You are here

GSK

GSK lifts annual profit forecast after third quarter beat on vaccines strength

Yahoo/Reuters

Wed, 10/30/19 - 10:08 am

GlaxoSmithKline's RIPK1 inhibitor dead on arrival

Fierce Biotech

Wed, 10/30/19 - 10:06 am

pancreatic cancer

Pfizer, GSK, J&J and more strike $248M deal to exit long-running Medicaid fraud suit

Fierce Pharma

Tue, 10/29/19 - 10:53 am

GSK’s TB vaccine makes a big step forward towards licensing

Pharmaforum

Tue, 10/29/19 - 09:46 am

GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test

Fierce Biotech

Mon, 10/28/19 - 10:55 am

antibiotic resistance

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

Endpoints

Thu, 10/24/19 - 10:08 am

PARP inhibitors

Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines

Pharmaceutical Business Review

Mon, 10/21/19 - 09:53 am

Bavarian Nordic

tick-borne encephalitis

GSK joins other drugmakers recalling Zantac products

Fierce Pharma

Wed, 10/9/19 - 11:01 pm

product recalls

GSK's ViiV launches first campaign for new HIV med Dovato with real patient ambassadors

Fierce Pharma

Wed, 10/9/19 - 09:49 am

ViiV Healthcare

GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma

Pharmaceutical Business Review

Fri, 10/4/19 - 09:59 am

Trelegy Ellipta

GSK’s Walmsley backs #MeTooPay gender pay campaign

Pharmaforum

Wed, 10/2/19 - 07:36 pm

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

Xconomy

Tue, 10/1/19 - 10:29 am

PARP inhibitors

prostate cancer

Seattle Genetics

GlaxoSmithKline's Nucala cuts severe asthma attacks in 'reassuring' interim real-world data

Fierce Pharma

Tue, 10/1/19 - 10:05 am

real world data

GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

Pharmaceutical Business Review

Tue, 10/1/19 - 09:56 am

clinicial trials

advanced ovarian cancer

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

Yahoo/Reuters

Sun, 09/29/19 - 11:57 am

ovarianc cancer

PARP inhibitors

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Fri, 09/27/19 - 09:10 am

GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO

BioSpace

Thu, 09/26/19 - 12:33 pm

PARP inhibitors

GlaxoSmithKline halts generic Zantac supply as global threat gains steam

Fierce Pharma

Thu, 09/26/19 - 10:50 am

product recalls

GSK invests $120M in biopharma plant as renewed oncology bets grow

Fierce Pharma

Wed, 09/25/19 - 11:37 pm

drug manufacturing

Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech

Endpoints

Wed, 09/25/19 - 09:16 am

Pages